- AU$33.90m
- -AU$33.93m
- AU$14.60m
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:33 AM
Brief: Immutep Seeks Trading Halt Pending Tacti-004 Trial Futility Analysis Outcome
Brief: Immutep Posts Half-Year Total Revenue And Other Income Of A$7.7 Million
Australia's Immutep hits 15-month high on positive IMP761 trial update
Australia's Immutep soars on partnering with India's Dr. Reddy’s
Brief: Immutep And Dr. Reddy's Enters Into Strategic Collaboration For Commercialisation Of An Innovative Oncology Drug, Eftilagimod Alfa
Brief: Dr Reddy's Unit Enters Strategic Collaboration With Immutep SAS
India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug (updated)
India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug
Brief: Immutep Enters Into Strategic Collaboration With Dr. Reddy's
Brief: Immutep Announces Successful Completion Of FDA Project Optimus Requirements
Brief: Immutep Announces Successful Completion Of US FDA Project Optimus Requirements
Brief: Immutep’s Sarcoma Trial Data Accepted for Oral Presentation at CTOS 2025